Harvard Apparatus Regenerative Technology (NSDQ:HART) said today it is rebranding as Biostage, Inc. and shifting its Nasdaq symbol to “BSTG”, effective April 1. The company said the brand shift “reflects the company’s broad commitment and expertise in pioneering the development of bioengineered organ implants for the esophagus, bronchus and trachea.” “The Biostage name change reflects the evolution of […]
Harvard Apparatus Regenerative Technology (HART)
HART targets artificial bronchus, esophagus for turnaround
Jim McGorry, CEO of Harvard Apparatus Regenerative Technology (NSDQ:HART), said he’s ready to right the ship at HART by expanding its regenerative trachea tech into both the bronchus and esophagus. McGorry has been the CEO of HART for 4 months, and told the Boston Business Journal he’s preparing to turn the company’s stock slide around. The reins were […]
HART CEO Green bows out | Personnel Moves
HART reveals death of artificial trachea patient
HART lands market exclusivity, pending FDA approval for artificial trachea
The FDA granted Harvard Apparatus Regenerative Technology (NSDQ:HART) 7 years of market exclusivity for its not-yet-approved HART-Trachea.
Press Release: Harvard Apparatus Regenerative Technology obtains orphan drug designation from U.S. FDA for HART-Trachea
HART CEO David Green on the transformative potential for regenerative medicine
World’s 1st regenerated trachea recipient faring well at 5 years
Insulet appoints 1st medical director | Personnel Moves
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Boston Scientific’s Irish ops pulled down $1.4B last year | Wall Street Beat
Boston Scientific (NYSE:BSX) posted pre-tax profits of $1.4 billion from its Irish unit and other foreign subsidiaries last year, according to the Irish Times.
Marlborough, Mass.-based medical device company Boston Scientific is 1 of the Emerald Isle’s largest employers, with a 4,500-employee workforce there.
